Go Pro
→ Iran War: What Happened at 1:11 P.M. Outside D.C.? (From Banyan Hill Publishing) (Ad)tc pixel Free AKTX Stock Alerts

Akari Therapeutics (AKTX) Competitors

Akari Therapeutics logo
$7.52 -0.02 (-0.27%)
Closing price 08/17/2026 04:00 PM Eastern
Extended Trading
$7.73 +0.21 (+2.79%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AKTX vs. ENLV, IZTC, BYSI, QNCX, and ESLA

Should you buy Akari Therapeutics stock or one of its competitors? Akari Therapeutics's main competitors and comparable companies include Enlivex Therapeutics (ENLV), Invizyne Technologies (IZTC), BeyondSpring (BYSI), Quince Therapeutics (QNCX), and Estrella Immunopharma (ESLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Akari Therapeutics compare to Enlivex Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Enlivex Therapeutics' return on equity of 248.08% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -147.45% -74.70%
Enlivex Therapeutics N/A 248.08%206.39%

Akari Therapeutics currently has a consensus price target of $32.33, suggesting a potential upside of 329.96%. Enlivex Therapeutics has a consensus price target of $247.50, suggesting a potential upside of 15,564.56%. Given Enlivex Therapeutics' higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Enlivex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, Akari Therapeutics and Akari Therapeutics both had 3 articles in the media. Akari Therapeutics' average media sentiment score of 0.30 equaled Enlivex Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enlivex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 32.2% of Akari Therapeutics shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Akari Therapeutics has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Enlivex TherapeuticsN/AN/A$1.24B-$8.25N/A

Summary

Enlivex Therapeutics beats Akari Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Akari Therapeutics compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

5.1% of Akari Therapeutics shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

Invizyne Technologies' return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Akari Therapeutics N/A -147.45%-74.70%

Akari Therapeutics has a consensus target price of $32.33, indicating a potential upside of 329.96%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akari Therapeutics is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Akari Therapeutics had 3 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for Akari Therapeutics and 0 mentions for Invizyne Technologies. Akari Therapeutics' average media sentiment score of 0.30 beat Invizyne Technologies' score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Invizyne Technologies Neutral
Akari Therapeutics Neutral

Summary

Akari Therapeutics beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

How does Akari Therapeutics compare to BeyondSpring?

Akari Therapeutics (NASDAQ:AKTX) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

In the previous week, BeyondSpring had 2 more articles in the media than Akari Therapeutics. MarketBeat recorded 5 mentions for BeyondSpring and 3 mentions for Akari Therapeutics. BeyondSpring's average media sentiment score of 1.15 beat Akari Therapeutics' score of 0.30 indicating that BeyondSpring is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BeyondSpring
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
BeyondSpringN/AN/A-$1.01M-$0.14N/A

Akari Therapeutics presently has a consensus price target of $32.33, indicating a potential upside of 329.96%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than BeyondSpring.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
BeyondSpring
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BeyondSpring's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -147.45% -74.70%
BeyondSpring N/A N/A -25.95%

Akari Therapeutics has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Summary

BeyondSpring beats Akari Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to Quince Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Akari Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by insiders. Comparatively, 7.1% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Akari Therapeutics and Akari Therapeutics both had 3 articles in the media. Quince Therapeutics' average media sentiment score of 1.63 beat Akari Therapeutics' score of 0.30 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Quince Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Akari Therapeutics presently has a consensus price target of $32.33, suggesting a potential upside of 329.96%. Quince Therapeutics has a consensus price target of $310.50, suggesting a potential upside of 810.02%. Given Quince Therapeutics' higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Quince Therapeutics
2 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.27

Quince Therapeutics' return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -147.45% -74.70%
Quince Therapeutics N/A N/A -154.49%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Quince TherapeuticsN/AN/A-$83.98M-$156.71N/A

Summary

Akari Therapeutics and Quince Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Akari Therapeutics compare to Estrella Immunopharma?

Akari Therapeutics (NASDAQ:AKTX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Akari Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Estrella Immunopharma's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -147.45% -74.70%
Estrella Immunopharma N/A N/A -328.72%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Estrella ImmunopharmaN/AN/A-$13.06M-$0.24N/A

Akari Therapeutics presently has a consensus price target of $32.33, indicating a potential upside of 329.96%. Estrella Immunopharma has a consensus price target of $8.00, indicating a potential upside of 952.35%. Given Estrella Immunopharma's higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Estrella Immunopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Akari Therapeutics and Akari Therapeutics both had 3 articles in the media. Estrella Immunopharma's average media sentiment score of 1.62 beat Akari Therapeutics' score of 0.30 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Estrella Immunopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Akari Therapeutics beats Estrella Immunopharma on 6 of the 10 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKTX vs. The Competition

Export
MetricAkari TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.63M$3.73B$7.03B$13.06B
Dividend YieldN/A3.69%2.56%10.63%
P/E RatioN/A11.49270.8125.39
Price / SalesN/A1,162.45560.8371.27
Price / CashN/A45.1128.8738.47
Price / Book0.3017.4111.166.51
Net Income-$17.30M-$13.19M$3.45B$347.22M
7 Day Performance-2.72%0.91%0.62%1.27%
1 Month Performance-31.70%2.63%2.09%2.72%
1 Year Performance-81.20%54.05%61.61%21.85%

Akari Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKTX
Akari Therapeutics
2.3533 of 5 stars		$7.52
-0.3%		$32.33
+330.0%		-81.4%$8.63MN/AN/A9
ENLV
Enlivex Therapeutics
3.0319 of 5 stars		$1.92
-4.5%		$247.50
+12,790.6%		-94.2%$33.83MN/AN/A70
IZTC
Invizyne Technologies
N/A$5.20
+1.9%		N/A-40.0%$32.51MN/AN/A29
BYSI
BeyondSpring
0.2238 of 5 stars		$0.79
+0.5%		N/A-64.8%$32.31M$1.75MN/A80
QNCX
Quince Therapeutics
3.0917 of 5 stars		$32.73
+6.8%		$568.40
+1,636.6%		-89.9%$31.17MN/AN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AKTX) was last updated on 8/18/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Iran War: What Happened at 1:11 P.M. Outside D.C.?
A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...
Banyan Hill Publishing | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
A Wall Street veteran shares two simple trading rules
A self-described Market Wizard says two simple rules, refined over decades on Wall Street, form the basis of h...
Brownstone Research | Sponsoredtc pixel
19 Factories. One AI Brain. One Hidden Stock.
A little-known aerospace manufacturer has linked 19 factories worldwide into a single AI-ready data system, dr...
The Oxford Club | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
A Dark Day Is Coming to America
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel